drugset / Trial / NCT04784442
A Dose-finding Trial of ETC-1002(Bempedoic Acid) in Patients With Hypercholesterolemia
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of this study is to assess the low-density lipoprotein cholesterol (LDL-C)-lowering efficacy and safety of ETC-1002(bempedoic acid) 60 mg, 120 mg and 180 mg versus placebo added to ongoing stable statin therapy or other lipid-modifying therapies in Japanese patients with hypercholesterolemia treated for 12 weeks.
Timeline
- Start
- 2021-03-24
- Primary completion
- 2022-04-18
- Completion
- 2022-05-17
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bempedoic acid | Small molecule | 60 mg | — |
| Subject | Bempedoic acid | Small molecule | 120 mg | — |
| Subject | Bempedoic acid | Small molecule | 180 mg | — |